-
1
-
-
84938953785
-
Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease
-
[1] Charlton, M., Everson, G.T., Flamm, S.L., Kumar, P., Landis, C., Brown, R.S., et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
-
(2015)
Gastroenterology
, vol.149
, pp. 649-659
-
-
Charlton, M.1
Everson, G.T.2
Flamm, S.L.3
Kumar, P.4
Landis, C.5
Brown, R.S.6
-
2
-
-
84952931354
-
Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis
-
[2] Curry, M.P., O'Leary, J.G., Bzowej, N., Muir, A.J., Korenblat, K.M., Fenkel, J.M., et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373 (2015), 2618–2628.
-
(2015)
N Engl J Med
, vol.373
, pp. 2618-2628
-
-
Curry, M.P.1
O'Leary, J.G.2
Bzowej, N.3
Muir, A.J.4
Korenblat, K.M.5
Fenkel, J.M.6
-
3
-
-
84991532636
-
Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV infection and decompensated cirrhosis: interim analysis of a French multicentre compassionate use programme European association for the study of the liver
-
The International Liver Congress Barcelona, Spain
-
[3] Leroy, V., Hezode, C., Metivier, S., Tateo, M., Conti, F., Nguyen-Khac, E., et al. Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV infection and decompensated cirrhosis: interim analysis of a French multicentre compassionate use programme European association for the study of the liver. 2016, The International Liver Congress, Barcelona, Spain.
-
(2016)
-
-
Leroy, V.1
Hezode, C.2
Metivier, S.3
Tateo, M.4
Conti, F.5
Nguyen-Khac, E.6
-
4
-
-
84991561168
-
Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV infection in patients with decompensated cirrhosis: results of a European Multicentre Compassionate Use Programme. European Association for the Study of the Liver
-
The International Liver Congress Barcelona, Spain
-
[4] Petersen, J., Welzel, T., Herzer, K., Ferenci, P., Gschwantler, M., Cornberg, M., et al. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV infection in patients with decompensated cirrhosis: results of a European Multicentre Compassionate Use Programme. European Association for the Study of the Liver. 2016, The International Liver Congress, Barcelona, Spain.
-
(2016)
-
-
Petersen, J.1
Welzel, T.2
Herzer, K.3
Ferenci, P.4
Gschwantler, M.5
Cornberg, M.6
-
5
-
-
84991593714
-
Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution
-
[5] Reig, M., Mariño, Z., Perelló, C., Iñarrairaegui, M., Ribeiro, A., Lens, S., et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 65 (2016), 719–726.
-
(2016)
J Hepatol
, vol.65
, pp. 719-726
-
-
Reig, M.1
Mariño, Z.2
Perelló, C.3
Iñarrairaegui, M.4
Ribeiro, A.5
Lens, S.6
-
6
-
-
84991568756
-
Development of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. European Association for the Study of the Liver
-
The International Liver Congress Barcelona, Spain
-
[6] Buonfiglioli, F., Conti, F., Andreone, P., Crespi, C., Foschi, G., Lenzi, M., et al. Development of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. European Association for the Study of the Liver. 2016, The International Liver Congress, Barcelona, Spain.
-
(2016)
-
-
Buonfiglioli, F.1
Conti, F.2
Andreone, P.3
Crespi, C.4
Foschi, G.5
Lenzi, M.6
-
7
-
-
0036242165
-
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
-
[7] Poynard, T., McHutchison, J., Manns, M., Trepo, C., Lindsay, K., Goodman, Z., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122 (2002), 1303–1313.
-
(2002)
Gastroenterology
, vol.122
, pp. 1303-1313
-
-
Poynard, T.1
McHutchison, J.2
Manns, M.3
Trepo, C.4
Lindsay, K.5
Goodman, Z.6
-
8
-
-
84871487025
-
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis
-
[8] van der Meer, A.J., Veldt, B.J., Feld, J.J., Wedemeyer, H., Dufour, J.F., Lammert, F., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2012), 2584–2593.
-
(2012)
JAMA
, vol.308
, pp. 2584-2593
-
-
van der Meer, A.J.1
Veldt, B.J.2
Feld, J.J.3
Wedemeyer, H.4
Dufour, J.F.5
Lammert, F.6
-
9
-
-
19944428400
-
Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival
-
[9] Shiratori, Y., Ito, Y., Yokosuka, O., Imazeki, F., Nakata, R., Tanaka, N., et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 142 (2005), 105–114.
-
(2005)
Ann Intern Med
, vol.142
, pp. 105-114
-
-
Shiratori, Y.1
Ito, Y.2
Yokosuka, O.3
Imazeki, F.4
Nakata, R.5
Tanaka, N.6
-
10
-
-
33947360829
-
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study
-
[10] Bruno, S., Stroffolini, T., Colombo, M., Bollani, S., Benvegnù, L., Mazzella, G., et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45 (2007), 579–587.
-
(2007)
Hepatology
, vol.45
, pp. 579-587
-
-
Bruno, S.1
Stroffolini, T.2
Colombo, M.3
Bollani, S.4
Benvegnù, L.5
Mazzella, G.6
-
11
-
-
84931560807
-
Liver EAfSo. EASL recommendations on treatment of hepatitis C 2015
-
[11] Liver EAfSo. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63 (2015), 199–236.
-
(2015)
J Hepatol
, vol.63
, pp. 199-236
-
-
-
12
-
-
84939653819
-
Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
-
[12] Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
-
(2015)
Hepatology
, vol.62
, pp. 932-954
-
-
-
13
-
-
84962086858
-
Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? The ironic conundrum in the era of effective and well-tolerated therapy
-
[13] Bunchorntavakul, C., Reddy, K.R., Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? The ironic conundrum in the era of effective and well-tolerated therapy. J Viral Hepat 23 (2016), 408–418.
-
(2016)
J Viral Hepat
, vol.23
, pp. 408-418
-
-
Bunchorntavakul, C.1
Reddy, K.R.2
-
14
-
-
84962847001
-
Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
-
[14] G.R. Foster W.L. Irving, Cheung, M.C., Walker, A.J., Hudson, B.E., Verma, S., et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64 (2016), 1224–1231.
-
(2016)
J Hepatol
, vol.64
, pp. 1224-1231
-
-
Foster, B.R.1
Irving, B.L.2
Cheung, M.C.3
Walker, A.J.4
Hudson, B.E.5
Verma, S.6
-
15
-
-
79952316752
-
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C
-
quiz e812
-
[15] Lok, A.S., Everhart, J.E., Wright, E.C., Di Bisceglie, A.M., Kim, H.Y., Sterling, R.K., et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 140 (2011), 840–849 quiz e812.
-
(2011)
Gastroenterology
, vol.140
, pp. 840-849
-
-
Lok, A.S.1
Everhart, J.E.2
Wright, E.C.3
Di Bisceglie, A.M.4
Kim, H.Y.5
Sterling, R.K.6
|